Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

Katharina Brück; Richard P. Meijer; Joost L. Boormans; Lambertus A. Kiemeney; J. Alfred Witjes; Lisa M.C. van Hoogstraten; Michiel S. van der Heijden; A. Rogier Donders; Martine Franckena; Carin A. Uyl-de Groot; Annemarie M. Leliveld-Kors; Katja K.H. Aben; Maarten C.C.M. Hulshof

doi:10.1007/s13629-026-00494-8

Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

Translated title of the contribution: Muscle-invasive bladder cancer in the Netherlands: oncological outcomes after radical cystectomy and bladder-sparing therapy

Katharina Brück^*
, Richard P. Meijer
, Joost L. Boormans
, Lambertus A. Kiemeney
, J. Alfred Witjes
, Lisa M.C. van Hoogstraten
, Michiel S. van der Heijden
, A. Rogier Donders
, Martine Franckena
, Carin A. Uyl-de Groot
, Annemarie M. Leliveld-Kors
, Katja K.H. Aben
, Maarten C.C.M. Hulshof
,

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5% for BPT and 55.3% for RC (HR 0.84; 95%-CI 0.69–1.05). Two-year OS was 74.0% for BPT versus 66.0% for RC (HR 0.80; 95%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.

Translated title of the contribution	Muscle-invasive bladder cancer in the Netherlands: oncological outcomes after radical cystectomy and bladder-sparing therapy
Original language	Dutch
Pages (from-to)	59-67
Number of pages	9
Journal	Tijdschrift voor Urologie
Volume	16
Issue number	2-3
DOIs	https://doi.org/10.1007/s13629-026-00494-8
Publication status	Published - Mar 2026

Keywords

Bladder-preserving therapy
Brachytherapy
Chemoradiation
Comparison
Disease-free survival
Muscle-invasive bladder cancer
Overall survival
Radical cystectomy
TMT
Trimodality treatment

Access to Document

10.1007/s13629-026-00494-8Licence: CC BY

s13629-026-00494-8Final published version, 793 KBLicence: CC BY

Cite this

Brück, K., Meijer, R. P., Boormans, J. L., Kiemeney, L. A., Witjes, J. A., van Hoogstraten, L. M. C., van der Heijden, M. S., Donders, A. R., Franckena, M., Uyl-de Groot, C. A., Leliveld-Kors, A. M., Aben, K. K. H., Hulshof, M. C. C. M. (2026). Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie. Tijdschrift voor Urologie, 16(2-3), 59-67. https://doi.org/10.1007/s13629-026-00494-8

@article{8aa0fed0abfd4f99945c5db02e757ec5,

title = "Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie",

abstract = "Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5\% for BPT and 55.3\% for RC (HR 0.84; 95\%-CI 0.69{\textendash}1.05). Two-year OS was 74.0\% for BPT versus 66.0\% for RC (HR 0.80; 95\%-CI 0.64{\textendash}0.98). DFS was comparable between groups, while OS favored BPT.",

keywords = "Bladder-preserving therapy, Brachytherapy, Chemoradiation, Comparison, Disease-free survival, Muscle-invasive bladder cancer, Overall survival, Radical cystectomy, TMT, Trimodality treatment",

author = "Katharina Br{\"u}ck and Meijer, \{Richard P.\} and Boormans, \{Joost L.\} and Kiemeney, \{Lambertus A.\} and Witjes, \{J. Alfred\} and \{van Hoogstraten\}, \{Lisa M.C.\} and \{van der Heijden\}, \{Michiel S.\} and Donders, \{A. Rogier\} and Martine Franckena and \{Uyl-de Groot\}, \{Carin A.\} and Leliveld-Kors, \{Annemarie M.\} and Aben, \{Katja K.H.\} and Hulshof, \{Maarten C.C.M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026.",

year = "2026",

month = mar,

doi = "10.1007/s13629-026-00494-8",

language = "Dutch",

volume = "16",

pages = "59--67",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "2-3",

}

Brück, K, Meijer, RP, Boormans, JL, Kiemeney, LA, Witjes, JA, van Hoogstraten, LMC, van der Heijden, MS, Donders, AR, Franckena, M, Uyl-de Groot, CA, Leliveld-Kors, AM, Aben, KKH, Hulshof, MCCM 2026, 'Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie', Tijdschrift voor Urologie, vol. 16, no. 2-3, pp. 59-67. https://doi.org/10.1007/s13629-026-00494-8

TY - JOUR

T1 - Spierinvasieve blaaskanker in Nederland

T2 - oncologische uitkomsten na radicale cystectomie en blaassparende therapie

AU - Brück, Katharina

AU - Meijer, Richard P.

AU - Boormans, Joost L.

AU - Kiemeney, Lambertus A.

AU - Witjes, J. Alfred

AU - van Hoogstraten, Lisa M.C.

AU - van der Heijden, Michiel S.

AU - Donders, A. Rogier

AU - Franckena, Martine

AU - Uyl-de Groot, Carin A.

AU - Leliveld-Kors, Annemarie M.

AU - Aben, Katja K.H.

AU - Hulshof, Maarten C.C.M.

N1 - Publisher Copyright: © The Author(s) 2026.

PY - 2026/3

Y1 - 2026/3

N2 - Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5% for BPT and 55.3% for RC (HR 0.84; 95%-CI 0.69–1.05). Two-year OS was 74.0% for BPT versus 66.0% for RC (HR 0.80; 95%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.

AB - Radical cystectomy (RC) is traditionally considered the standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC), although randomized evidence of superiority over bladder-preserving therapy (BPT) is lacking. In this nationwide study, we included all patients diagnosed with non-metastatic MIBC between 2017 and 2019 and treated with curative-intent with either RC or BPT. A total of 1,432 patients were included (1,101 RC, 331 BPT). The primary endpoint was 2‑year disease-free survival (DFS), with overall survival (OS) as the secondary endpoint. IPTW-adjusted 2‑year DFS was 61.5% for BPT and 55.3% for RC (HR 0.84; 95%-CI 0.69–1.05). Two-year OS was 74.0% for BPT versus 66.0% for RC (HR 0.80; 95%-CI 0.64–0.98). DFS was comparable between groups, while OS favored BPT.

KW - Bladder-preserving therapy

KW - Brachytherapy

KW - Chemoradiation

KW - Comparison

KW - Disease-free survival

KW - Muscle-invasive bladder cancer

KW - Overall survival

KW - Radical cystectomy

KW - TMT

KW - Trimodality treatment

UR - https://www.scopus.com/pages/publications/105031942996

U2 - 10.1007/s13629-026-00494-8

DO - 10.1007/s13629-026-00494-8

M3 - Article

AN - SCOPUS:105031942996

SN - 2211-3037

VL - 16

SP - 59

EP - 67

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 2-3

ER -

Spierinvasieve blaaskanker in Nederland: oncologische uitkomsten na radicale cystectomie en blaassparende therapie

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this